mAb-话题@MedSci

#mAb#

1302篇内容 | 2884人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912566, encodeId=f79e191256692, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=礼来的donanemab治疗阿尔茨海默症，结果好坏参半, objectType=article, longId=208445, objectId=702020844586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=702020844586, replyNumber=0, likeNumber=71, createdTime=2022-01-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=702020844586, moduleTitle=礼来的donanemab治疗阿尔茨海默症，结果好坏参半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=702020844586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912536, encodeId=5c931912536da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=CD73抗体Uliledlimab治疗肿瘤，已在中国和美国的多项临床试验中取得进展, objectType=article, longId=206931, objectId=5dc82069316f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dc82069316f, replyNumber=0, likeNumber=53, createdTime=2021-05-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dc82069316f, moduleTitle=CD73抗体Uliledlimab治疗肿瘤，已在中国和美国的多项临床试验中取得进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dc82069316f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912403, encodeId=ba1a191240386, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA接受Tralokinumab治疗中重度特应性皮炎的BLA, objectType=article, longId=197354, objectId=32da19e35447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32da19e35447, replyNumber=0, likeNumber=50, createdTime=2021-06-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32da19e35447, moduleTitle=FDA接受Tralokinumab治疗中重度特应性皮炎的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32da19e35447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912522, encodeId=cb6719125224d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性, objectType=article, longId=206100, objectId=b08320610035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b08320610035, replyNumber=0, likeNumber=68, createdTime=2021-09-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b08320610035, moduleTitle=复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b08320610035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912393, encodeId=53611912393d4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：巨噬细胞低吞噬作用介导mAb诱导性细胞清除的免疫耐受, objectType=article, longId=196210, objectId=ce1b1962104a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1b1962104a, replyNumber=0, likeNumber=62, createdTime=2021-05-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1b1962104a, moduleTitle=Blood：巨噬细胞低吞噬作用介导mAb诱导性细胞清除的免疫耐受, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1b1962104a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912523, encodeId=70e11912523d7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=单药化疗耐药的滋养细胞肿瘤Avelumab 治疗安全有效, objectType=article, longId=206090, objectId=26c6206090a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26c6206090a9, replyNumber=0, likeNumber=83, createdTime=2021-12-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26c6206090a9, moduleTitle=单药化疗耐药的滋养细胞肿瘤Avelumab 治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26c6206090a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912458, encodeId=ff731912458c9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, objectType=article, longId=202091, objectId=a75320209101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75320209101, replyNumber=0, likeNumber=89, createdTime=2020-12-30, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75320209101, moduleTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75320209101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912546, encodeId=766d19125461a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Toripalimab联合化学疗法一线治疗鼻咽癌，中国国家药品监督管理局已批准其补充性新药申请, objectType=article, longId=207388, objectId=e5a120e38811, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5a120e38811, replyNumber=0, likeNumber=71, createdTime=2021-09-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5a120e38811, moduleTitle=Toripalimab联合化学疗法一线治疗鼻咽癌，中国国家药品监督管理局已批准其补充性新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5a120e38811)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912493, encodeId=83ee1912493a5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, objectType=article, longId=203842, objectId=f57420384247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57420384247, replyNumber=0, likeNumber=61, createdTime=2021-09-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57420384247, moduleTitle=“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57420384247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912460, encodeId=2f26191246099, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, objectType=article, longId=202280, objectId=18ae2022800c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ae2022800c, replyNumber=0, likeNumber=100, createdTime=2021-08-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ae2022800c, moduleTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ae2022800c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912349, encodeId=16bc191234938, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, objectType=article, longId=193433, objectId=e611193433d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e611193433d4, replyNumber=0, likeNumber=77, createdTime=2021-02-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e611193433d4, moduleTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e611193433d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912533, encodeId=26d3191253353, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, objectType=article, longId=206790, objectId=0006206e9068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0006206e9068, replyNumber=0, likeNumber=70, createdTime=2021-03-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0006206e9068, moduleTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0006206e9068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912482, encodeId=ef971912482bd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=58, createdTime=2020-12-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912350, encodeId=c3b01912350f9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, objectType=article, longId=193523, objectId=093019352369, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=093019352369, replyNumber=0, likeNumber=80, createdTime=2020-09-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=093019352369, moduleTitle=FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=093019352369)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912485, encodeId=8ab3191248561, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Jpn J Clin Oncol：研究人员在晚期食管鳞状细胞癌患者血清中发现了能够预测对nivolumab反应的候选miRNAs, objectType=article, longId=203359, objectId=97b9203359d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97b9203359d3, replyNumber=0, likeNumber=71, createdTime=2021-01-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97b9203359d3, moduleTitle=Jpn J Clin Oncol：研究人员在晚期食管鳞状细胞癌患者血清中发现了能够预测对nivolumab反应的候选miRNAs, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97b9203359d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912542, encodeId=67d01912542a1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NHS将为COVID-19患者提供Tocilizumab, objectType=article, longId=207135, objectId=aa3220e135c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa3220e135c8, replyNumber=0, likeNumber=72, createdTime=2021-07-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa3220e135c8, moduleTitle=NHS将为COVID-19患者提供Tocilizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa3220e135c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912549, encodeId=75051912549a8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果, objectType=article, longId=207490, objectId=06e320e49013, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06e320e49013, replyNumber=0, likeNumber=100, createdTime=2021-10-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06e320e49013, moduleTitle=J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06e320e49013)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912445, encodeId=4377191244523, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, objectType=article, longId=201254, objectId=80e12012542c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e12012542c, replyNumber=0, likeNumber=0, createdTime=2020-12-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e12012542c, moduleTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e12012542c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912471, encodeId=372e19124e1c8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=阿尔茨海默症新药aducanumab上市申请又有新动态, objectType=article, longId=202830, objectId=5ed8202830b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ed8202830b6, replyNumber=0, likeNumber=58, createdTime=2021-03-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ed8202830b6, moduleTitle=阿尔茨海默症新药aducanumab上市申请又有新动态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ed8202830b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912420, encodeId=7b0a191242042, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Haematol：Avadomide联合obinutuzumab治疗复发性或难治性非霍奇金淋巴瘤, objectType=article, longId=198711, objectId=97c8198e11f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c8198e11f4, replyNumber=0, likeNumber=66, createdTime=2021-06-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c8198e11f4, moduleTitle=Lancet Haematol：Avadomide联合obinutuzumab治疗复发性或难治性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c8198e11f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

礼来的donanemab治疗阿尔茨海默症，结果好坏参半

2022-01-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

CD73抗体Uliledlimab治疗肿瘤，已在中国和美国的多项临床试验中取得进展

2021-05-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA接受Tralokinumab治疗中重度特应性皮炎的BLA

2021-06-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

复发或晚期错配修复缺陷的子宫内膜癌：Dostarlimab的临床活性和安全性

2021-09-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：巨噬细胞低吞噬作用介导mAb诱导性细胞清除的免疫耐受

2021-05-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

单药化疗耐药的滋养细胞肿瘤Avelumab 治疗安全有效

2021-12-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症

2020-12-30

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Toripalimab联合化学疗法一线治疗鼻咽癌，中国国家药品监督管理局已批准其补充性新药申请

2021-09-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

“Gene MAb递送系统”治疗COVID-19的II期临床研究，已获得资金支持

2021-09-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见

2021-08-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价

2021-02-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效

2021-03-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2020-12-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准Darzalex（daratumumab）皮下制剂治疗多发性骨髓瘤

2020-09-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Jpn J Clin Oncol：研究人员在晚期食管鳞状细胞癌患者血清中发现了能够预测对nivolumab反应的候选miRNAs

2021-01-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NHS将为COVID-19患者提供Tocilizumab

2021-07-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Andecaliximab联合mFOLFOX6方案作为晚期胃/胃食管交界腺癌的一线疗法的3期试验结果

2021-10-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）

2020-12-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

阿尔茨海默症新药aducanumab上市申请又有新动态

2021-03-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Haematol：Avadomide联合obinutuzumab治疗复发性或难治性非霍奇金淋巴瘤

2021-06-07

科室
- - 订阅+
  - 更多科室
工具
服务